A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-186 (also known as MVC-101), An EGFR x CD3 COnditional Bispecific Redirected Activation (COBRA) Protein in Patients with Unresectable Locally Advanced or Metastatic Cancer

Is this Study for You?

Let's Get Started!

Details
Age

Adult

Locations

CTRC Inpatient
University of Colorado Hospital

Principal Investigator
Photograph of Tejas Patil

Tejas Patil

Study ID

Protocol Number: 23-1245

More information available at ClinicalTrials.gov: NCT04844073

Categories

Is this Study for You?

Let's Get Started!

Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers